Global SUMOylation is a molecular mechanism underlying hypothermia-induced ischemic tolerance

被引:40
作者
Lee, Yang-ja [1 ]
Mou, Yougshan [1 ]
Klimanis, Dace [1 ]
Bernstock, Joshua D. [1 ]
Hallenbeck, Johnm. [1 ]
机构
[1] NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA
来源
FRONTIERS IN CELLULAR NEUROSCIENCE | 2014年 / 8卷
关键词
Hypothermia; SUMOylation; pMCAO; Neuroprotection; Ubc9; FOCAL CEREBRAL-ISCHEMIA; STROKE THERAPY; PROTEIN SUMOYLATION; SUMO; MICE; CONJUGATION; BRAIN; CELLS; INDUCTION; NEURONS;
D O I
10.3389/fncel.2014.00416
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The molecular mechanisms underlying hypothermic neuroprotection have yet to be fully elucidated. Herein we demonstrate that global SUMOylation, a form of post-translational modification with the Small Ubiquitin-like MOdifer, participates in the multimodal molecular induction of hypothermia-induced ischemic tolerance. Mild (32 degrees C) to moderate (28 degrees C) hypothermic treatment(s) during OGD (oxygen-glucose-deprivation) or ROG (restoration of oxygen/glucose) increased global SUMO-conjugation levels and protected cells (both SHSY5Y and E18 rat cortical neurons) from OGD and ROG-induced cell death. Hypothermic exposure either before or after permanent middle cerebral artery occlusion (pMCAO) surgery in wild type mice increased global SUMO-conjugation levels in the brain and in so doing protected these animals from pMCAO-induced ischemic damage. Of note, hypothermic exposure did not provide an additional increase in protection from pMCAO-induced ischemic brain damage in Ubc9 transgenic (Ubc9 Tg) mice, which overexpress the sole E2 SUMO conjugating enzyme and thereby display elevated basal levels of global SUMOylation under normothermic conditions. Such evidence suggests that increases in global SUMOylation are critical and may account for a substantial part of the observed increase in cellular tolerance to brain ischemia caused via hypothermia. Keywords: Hypothermia.
引用
收藏
页数:9
相关论文
共 45 条
  • [11] Gonzalez-Ibarra Fernando Pavel, 2011, Front Neurol, V2, P4, DOI 10.3389/fneur.2011.00004
  • [12] The many faces of tumor necrosis factor in stroke
    Hallenbeck, JM
    [J]. NATURE MEDICINE, 2002, 8 (12) : 1363 - 1368
  • [13] STROKE THERAPY - IT MAY BE TIME FOR AN INTEGRATED APPROACH
    HALLENBECK, JM
    FRERICHS, KU
    [J]. ARCHIVES OF NEUROLOGY, 1993, 50 (07) : 768 - 770
  • [14] SUMO: A history of modification
    Hay, RT
    [J]. MOLECULAR CELL, 2005, 18 (01) : 1 - 12
  • [15] Ubc9 is essential for viability of higher eukaryotic cells
    Hayashi, T
    Seki, M
    Maeda, D
    Wang, WS
    Kawabe, Y
    Seki, T
    Saitoh, H
    Fukagawa, T
    Yagi, H
    Enomoto, T
    [J]. EXPERIMENTAL CELL RESEARCH, 2002, 280 (02) : 212 - 221
  • [16] Stroke research at a crossroad: asking the brain for directions
    Iadecola, Costantino
    Anrather, Josef
    [J]. NATURE NEUROSCIENCE, 2011, 14 (11) : 1363 - 1368
  • [17] Neuyotensin-induced hypotheymia improves neurologic outcome after hypoxic-ischemia
    Katz, LM
    Young, A
    Frank, JE
    Wang, YF
    Park, K
    [J]. CRITICAL CARE MEDICINE, 2004, 32 (03) : 806 - 810
  • [18] Cooling in intracerebral hemorrhage (CINCH) trial: protocol of a randomized German-Austrian clinical trial
    Kollmar, Rainer
    Juettler, Eric
    Huttner, Hagen B.
    Doerfler, Arnd
    Staykov, Dimitre
    Kallmuenzer, Bernd
    Schmutzhard, Erich
    Schwab, Stefan
    Broessner, Gregor
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2012, 7 (02) : 168 - 172
  • [19] Therapeutic hypothermia for acute ischemic stroke - What do laboratory studies teach us?
    Krieger, DW
    Yenari, MA
    [J]. STROKE, 2004, 35 (06) : 1482 - 1489
  • [20] BW619C89, A GLUTAMATE RELEASE INHIBITOR, PROTECTS AGAINST FOCAL CEREBRAL ISCHEMIC DAMAGE
    LEACH, MJ
    SWAN, JH
    EISENTHAL, D
    DOPSON, M
    NOBBS, M
    [J]. STROKE, 1993, 24 (07) : 1063 - 1067